Microbial metabolism of dietary components has been causally linked to cardiovascular disease and atherosclerosis. Now, Wang et al. demonstrate that inhibition of microbial TMA lyases, essential for production of pro-atherogenic trimethylamines, prevents atherosclerosis in vivo.
The normal gut microbiota is a major regulator of host metabolism and has been causally linked to fat gain and impairment of glucose metabolism (Bä ckhed et al., 2004) . Obesity and insulin resistance are two hallmarks of metabolic syndrome, which is associated with increased risk of developing cardiovascular disease (CVD). Closing the circle, atherosclerosis and CVD have been associated with alterations in the gut microbiome and in microbial capacity to produce bio-active components (Karlsson et al., 2012) , suggesting that direct targeting of the gut microbiome could represent a novel and attractive platform to treat cardiometabolic disease.
In this issue of Cell, Wang et al. describe a strategy for targeting trimethylamine (TMA) lyases, enzymes that mediate the microbial metabolism of dietary choline to TMA (Wang et al., 2015) . TMA is further oxidized to trimethylamine N-oxide (TMAO) by the hepatic enzyme flavin monooxygenase 3 (FMO3) and serves as a predictive marker for CVD (Tang et al., 2013) . Supplementing diet with TMAO increased the level of atherosclerosis in mice (Wang et al., 2011) , implicating TMA/TMAO as potentially causative agents in CVD. Directly blocking FMO3 may have potential metabolic beneficial effects but would come with an extremely undesirable side effect: the resulting TMA accumulation generates a noxious odor, characteristic of the ''fish odor syndrome.'' However, blocking TMAO synthesis without accumulation of TMA could be a much more attractive alternative.
Wang et al. identify a small-molecule, 3,3-dimethyl-1-butanol (DMB), which is a substrate mimic of choline and functions as a potent TMA lyase inhibitor against a diverse and phylogenetically distant range of TMA lyases ( Figure 1 ) (Wang et al., 2015) . In a series of elegant experiments, the authors demonstrate that the inhibitor also has effects against carnitine, an alternative substrate for TMA lyases, and that DMB also inhibits TMA production from polymicrobial human fecal samples. DMB appears to be a nontoxic compound naturally found in, for example, olive oils and red wines. Importantly, DMB does not kill the gut bacteria; it is much less likely to generate bacterial resistance to the drug, and therefore it would be an ideal candidate drug candidate for treating atherosclerosis.
Atherosclerosis is characterized by accumulation of lipids and infiltration of immune cells in the large arteries (Hansson, 2005) . Oxidized LDL is accumulated in the lesions and is taken up by infiltrating macrophages that subsequently convert to lipid-rich foam cells. This process can be prevented by reverse cholesterol transport. TMAO has been shown to inhibit reverse cholesterol transport from the macrophages, thus promoting harmful foam cell formation choline and DMB show that the TMA lyase inhibitor reduces the level of bacterial taxa that are positively associated with the plasma levels of TMA, TMAO, and aortic root lesion area. Previous work has shown that antibiotic-treated mice were partially protected from carnitine-or choline-induced atherosclerosis, linking the gut microbiota to atherosclerosis Wang et al., 2011) . Here, without depleting the entire gut microbial community but, rather, specifically inhibiting a microbial enzyme, the authors show that inhibiting the choline-to-TMAO pathway seems to be an effective target for treating atherosclerotic disease, along with a change in the gut microbiota to a more host-beneficial community.
These findings highlight the importance of specific food components and subsequent interaction with the gut microbiota that produce potentially harmful metabolites and can affect disease progression. In the future, it will be important to investigate whether DMB also inhibits atherosclerosis in Apoe À/À mice fed a Western diet, including high choline concentration, and to further investigate whether blocking of the TMA/TMAO pathway is a viable therapeutic strategy for treatment of CVD in humans. It is tempting to speculate also whether other diseases in which microbial metabolites are supposedly implicated in the pathology-as, for example, autism spectrum disorder (Hsiao et al., 2013 )-may also benefit from approaches such as that reported here. In fact, as we continue to uncover the relationship between microbial metabolites and human diseases, drugging microbial metabolism may deeply reshape the way that we treat diseases in the future: no longer focused on the host solely but, rather, on the intimacy of the host-microbiota relationship.
How stochastic is gene expression in mammalian cells? Not very, according to Battich et al., who report that single-cell variability in cytoplasmic mRNAs is remarkably predictable given measurements of a cell's phenotypic state and microenvironment. The noise from transcriptional bursts is buffered by a hallmark of eukaryotes-the nucleus.
Transcription of a gene is noisy business. Permissive chromatin states must combine with transcription factors, coactivators, and polymerase at a single locus to make RNA. When these conditions are right, transcription from the DNA template yields a stochastic burst of primary RNA copies with burst size and frequency depending on the genomic context (Dar et al., 2012) . Transcriptional noise gives rise to cell-to-cell variability that is exploited by viruses, bacteria, and fungi (Raj and van Oudenaarden, 2008) . By contrast, the intrinsic noise of transcription is ordinarily a problem for metazoans that must reproducibly coordinate cellular functions during tissue morphogenesis and homeostasis (Wang et al., 2012) . When isogenic mammalian cells are cultured in vitro, there is a loss of coordination, and transcript abundances appear highly variable (Figure 1) . Such cell-to-cell heterogeneity could reflect uncontrolled transcriptional bursting or more-predictable regulation from extrinsic factors that are specific to the context of each individual cell. By combining single-cell counting of cytoplasmic transcripts with various data-driven modeling approaches, Pelkmans and coworkers, in this issue of Cell, argue strongly for the latter (Battich et al., 2015) . The noise from transcriptional bursts is dampened by retention of
